Drug discovery

BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca

Retrieved on: 
Thursday, October 6, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, Knowledge, AstraZeneca, Euronext, Disease, Chronic kidney disease, IPF, Google Knowledge Graph, BAI, Research, Benevolence, Probability, Drug discovery, Idiopathic pulmonary fibrosis, Biopharmaceutical, AMS, Chemistry, Genetics, CKD, Euronext Amsterdam, Platform, Medical device, Pharmaceutical industry

The long-term collaboration, initiated in 2019, combines BenevolentAIs proprietary AI-enabled drug discovery platform, the Benevolent Platform, with AstraZenecas disease expertise to identify novel targets.

Key Points: 
  • The long-term collaboration, initiated in 2019, combines BenevolentAIs proprietary AI-enabled drug discovery platform, the Benevolent Platform, with AstraZenecas disease expertise to identify novel targets.
  • BenevolentAI and AstraZeneca scientists work side-by-side, using the Platform and Knowledge Graph to interrogate underlying disease mechanisms, frame and test hypotheses and rapidly identify novel targets.
  • Joanna Shields, Chief Executive Officer at BenevolentAI, commented: We are pleased that AstraZeneca has selected a further two novel targets from our collaboration to enter its portfolio.
  • Our ongoing collaboration with BenevolentAI is helping us to uncover novel rare variants of complex diseases, such as IPF and CKD.

Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)

Retrieved on: 
Wednesday, October 5, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Infection, Therapy, Immunotherapy, SITC, IL-7, Cytokine, Degenerative disease, JITC, Cancer, Technology, Society for Immunotherapy of Cancer, Drug discovery, Society, Journal, Maintenance, Half-life, Pharmaceutical industry, Vaccine, Safety

A second poster will detail preclinical data on MDK-1654, Medikines dual-acting agonist that incorporates both IL-7 and non-alpha IL-2/15 PEPTIKINEs.

Key Points: 
  • A second poster will detail preclinical data on MDK-1654, Medikines dual-acting agonist that incorporates both IL-7 and non-alpha IL-2/15 PEPTIKINEs.
  • Posters will also be available on the Medikine website at www.Medikine.com following the poster presentations.
  • These PEPTIKINES are engineered for low immunogenicity and are readily amenable to the incorporation of targeting and other pharmacological features.
  • Medikines lead candidate, MDK-703, currently in a Phase 1 clinical trial in healthy volunteers, is an IL-7 PEPTIKINE fused to an immunoglobulin Fc-domain.

Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology

Retrieved on: 
Wednesday, October 5, 2022
Research, Genetics, Fitness & Nutrition, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Method, Medicine, IND, Immunity, University of Copenhagen, Nobel Prize, Neoplasm, Patient, Drug development, Biology, Biotechnology, Research, Partnership, Cancer, University, Nobel Prize in Chemistry, Scripps Research, Immune system, Drug discovery, Pharmacokinetics, Safety, Medication, Glycosylation, Copenhagen, Inflammation, Click chemistry, NCT, Secondary research, Pharmaceutical industry, Palleon, Chemistry

Palleon Pharmaceuticals , a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the companys scientific co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry.

Key Points: 
  • Palleon Pharmaceuticals , a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the companys scientific co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry.
  • Dr. Bertozzi invented the field of bioorthogonal chemistry, which allows researchers to chemically modify molecules in living systems without interfering with normal cell functions.
  • Dr. Sharpless is an American scientist who previously won the Nobel Prize for Chemistry in 2001.
  • Palleon Pharmaceuticals is a biotechnology company pioneering glyco-immunology drug development to transform the treatment of cancer and inflammatory diseases.

Twist Bioscience to Present at JSNN NanoImpacts 2022

Retrieved on: 
Wednesday, October 5, 2022
Other Health, Research, General Health, Pharmaceutical, Technology, Semiconductor, Genetics, Clinical Trials, Science, Nanotechnology, Biotechnology, Health, Conference, Agriculture, Genomics, SSBR, NASDAQ, Silicon, Synthetic biology, Biology, Technology, Twist Bioscience, Goal, Drug discovery, NGS, Martek Biosciences Corporation, Gorman Joint School District, DNA, Engineering

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Joint School of Nanoscience and Nanoengineering (JSNN) NanoImpacts 2022: Semiconductor Synthetic Biology and Beyond taking place October 13-15, 2022 in Greensboro, NC.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Joint School of Nanoscience and Nanoengineering (JSNN) NanoImpacts 2022: Semiconductor Synthetic Biology and Beyond taking place October 13-15, 2022 in Greensboro, NC.
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) TCR and BCR Kits for Comprehensive Immune Repertoire Profiling

Retrieved on: 
Wednesday, October 5, 2022
TCR, BCR, AIR, UMI, Cell engineering, RNA interference, Technology, PCR, Biomarker, PBMC, Drug discovery, Industry, NGS, Complementarity, CRISPR, CDR3, Vaccine

MOUNTAIN VIEW, Calif., Oct. 5, 2022 /PRNewswire/ -- Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) TCR and BCR kits, a family of multiplex-PCR, NGS-based assays that enable profiling of up to all seven T-cell receptor (TCR) and B-cell receptor (BCR) chains from the same sample, in a single tube, without need of specialized equipment.

Key Points: 
  • Subsequent sequencing and analysis identify antigen-activated clonotypes which can provide insight into the adaptive immune response and is useful for a wide range of therapeutic and diagnostic applications.
  • "While there are numerous immune receptor profiling options available on the market today, there are none that provide the comprehensive, highly sensitive and quantifiable results provided by the DriverMap AIR TCR and BCR assays.
  • Unbiased, cost-effective profiling of all TCR/BCR mRNA isoforms in a single assay and quantitative immune receptor repertoire coverage of abundant clonotypes from whole blood, PBMC, FFPE, tissue or purified immune cells.
  • In addition to the DriverMap AIR kits, Cellecta continues to provide the DriverMap AIR Profiling assay as a service for collaborators working in a variety of therapeutic areas.

Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
U.S. Securities and Exchange Commission, Scientific programming language, Therapy, SITC, Infection, GMP, Annual report, NASDAQ, Neoplasm, Twitter, Security (finance), Annual general meeting, Immunotherapy, Risk, Society for Immunotherapy of Cancer, Cancer, University, Publication, Company, Immune system, Doctor of Philosophy, Education, Mink, Society, FC, Drug discovery, 2021 Essex County Council election, Toxic epidermal necrolysis, GLOBE, Clinical research, Pancreatic cancer, Leadership, Vaccine, Pharmaceutical industry, MD, Agenus

To register for the webinar, please visit the Educational and Scientific Programs section of the SITC website .

Key Points: 
  • To register for the webinar, please visit the Educational and Scientific Programs section of the SITC website .
  • Updated data presented at the conference will be available to view in the Publications section of the Agenus website (https://agenusbio.com/publications) following the SITC Annual Meeting.
  • Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections.
  • Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release.

Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio

Retrieved on: 
Wednesday, October 5, 2022
FSE, CSO, Development, IND, Family II, Otsuka Pharmaceutical, LLC, Patient, Mental health, Treatment, Drug discovery, CSE, CEO, CNS, Patent, Psilocybin, GLOBE, USPTO, Half-life, MSET, CRO, Pharmaceutical industry, Mindset

Through a world class scientific collaboration among the Mindset, MSRD and Otsuka Pharmaceuticals teams, Mindset has successfully moved its Family 2 program forward.

Key Points: 
  • Through a world class scientific collaboration among the Mindset, MSRD and Otsuka Pharmaceuticals teams, Mindset has successfully moved its Family 2 program forward.
  • After extensively screening multiple drug candidates in preclinical studies, we were able to identify not one, but two novel drug candidates to potentially advance to clinical human trials.
  • We are delighted to have reached this major milestone in our programs development, said James Lanthier, CEO of Mindset Pharma.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Global Bioanalytical Testing Services Markets, 2021-2022 & 2027: Leading Growth Opportunity Areas in Customized Bioassay and Biomarker Testing Services - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022
Pharmaceutical, Health, Biometrics, Adoption, LIMS, Cros, RNA transfection, Assay, PD, Growth, Drug development, Artificial intelligence, Technology, Drug discovery, Industry, Pharmacokinetics, Ecosystem, CRO, COVID-19, Solution, Toxicology, Semiconductor, Fine chemical

This report on global bioanalytical testing services identifies some of the leading growth opportunity areas in terms of customized bioassay and biomarker testing services, highlighting the growing trend of CRO subcontracting to specifically cater to the specialized drug development and accuracy needs.

Key Points: 
  • This report on global bioanalytical testing services identifies some of the leading growth opportunity areas in terms of customized bioassay and biomarker testing services, highlighting the growing trend of CRO subcontracting to specifically cater to the specialized drug development and accuracy needs.
  • Bioanalytical testing is one of the core aspects of drug development.
  • The testing modules include biomarker testing, immunogenicity testing, toxicology, pharmacokinetics (PK), and pharmacodynamics (PD).
  • What are key trends driving and restricting the outsourcing of bioanalytical testing services?

Global Bioreactors Market Research and Forecast, 2022-2028: Extensive Applications in Growing Life Sciences Industry Fuels Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022
Health, Biometrics, Adoption, News, Microbiology, Stainless steel, Cros, Growth, Vaccine, CAGR, Asthma, PH, Cancer, Precision medicine, Temperature, Drug discovery, Bioreactor, Bacteria, Contract, Degenerative disease, Oxygen, Landfill, Fine chemical, Marketing

The global bioreactor market is anticipated to grow at a significant CAGR of 10.3% during the forecast period (2021-2027).

Key Points: 
  • The global bioreactor market is anticipated to grow at a significant CAGR of 10.3% during the forecast period (2021-2027).
  • With the growing life science industry globally, bioreactors are extensively being used in the production of monoclonal antibodies, recombinant therapeutics, drug discovery, and so forth.
  • However, challenges associated with the use of bioreactors such as non-customizable and difficult to scale may hinder the global bioreactor market growth.
  • Additionally, the short shelf-life of industrial microbiology reagents is also creating challenges as well as an opportunity for the bioreactors market.

Valence Discovery Grows Leadership Team with Key Drug Discovery Hires

Retrieved on: 
Wednesday, October 5, 2022
Research, Technology, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Artificial Intelligence, Merck, GSK, Cardiovascular disease, Therapy, IND, Pfizer, R, Precision medicine, Drug discovery, Atlas, Health, AI, Novartis, Virology, CEO, Autoimmunity, RA, Atlas Venture, Third Rock Ventures, Pharmaceutical industry, Fine chemical, Medical device, Chemistry

We are thrilled to welcome Guillaume, Mike, and Brian to the team as we deploy our platform to build our pipeline of internal drug discovery programs.

Key Points: 
  • We are thrilled to welcome Guillaume, Mike, and Brian to the team as we deploy our platform to build our pipeline of internal drug discovery programs.
  • Guillaume Barbe, Ph.D. brings more than 15 years of drug discovery and development experience across multiple therapeutic areas, including oncology, autoimmunity, cardiovascular disease, and virology.
  • Guillaume joins Valence after spending several years as a biotech executive building, managing, and leading drug discovery teams within RA Ventures and Third Rock Ventures portfolio companies.
  • Valence is uniquely positioned to deliver on the promise of AI-driven drug discovery and development, said Dr. Barbe.